<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Phys Ther</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Phys Ther</journal-id><journal-title-group><journal-title>Brazilian Journal of Physical Therapy</journal-title></journal-title-group><issn pub-type="ppub">1413-3555</issn><issn pub-type="epub">1809-9246</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o Brasileira de Pesquisa e P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em
Fisioterapia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24838809</article-id><article-id pub-id-type="pmc">4183253</article-id><article-id pub-id-type="doi">10.1590/S1413-35552012005000151</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Costs and benefits of Pulmonary Rehabilitation in Chronic Obstructive
Pulmonary Disease: a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Farias</surname><given-names>Catharinne C.</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Resqueti</surname><given-names>Vanessa</given-names></name><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Dias</surname><given-names>Fernando A. L.</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Borghi-Silva</surname><given-names>Audrey</given-names></name><xref ref-type="aff" rid="aff03">3</xref></contrib><contrib contrib-type="author"><name><surname>Arena</surname><given-names>Ross</given-names></name><xref ref-type="aff" rid="aff04">4</xref></contrib><contrib contrib-type="author"><name><surname>Fregonezi</surname><given-names>Guilherme A. F.</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="corresp" rid="c01"/></contrib></contrib-group><aff id="aff01"><label>1</label> Physical Therapy Department, Universidade Federal do Rio Grande do
Norte (UFRN), Natal, RN, Brazil</aff><aff id="aff02"><label>2</label> Physical Therapy Department, Universidade Federal de Pernambuco
(UFPE), Recife, PE, Brazil</aff><aff id="aff03"><label>3</label> Physical Therapy Department, Universidade Federal de S&#x000e3;o Carlos
(UFSCar), S&#x000e3;o Carlos, SP, Brazil</aff><aff id="aff04"><label>4</label> Physical Therapy Department, College of Applied Health Sciences,
University of Illinois Chicago, Chicago,IL, USA </aff><author-notes><corresp id="c01"><bold>Correspondence: Guilherme Augusto de Freitas Fregonezi,</bold>
Universidade Federal do Rio Grande do Norte, Departamento de Fisioterapia
Pneumocardiovascular, Performance &#x00026; Respiratory Muscle Laboratory, Caixa
Postal 1524, Campus Universit&#x000e1;rio Lagoa Nova, CEP 59072-970, Natal, RN, Brazil.
e-mail: <email>fregonezi@ufrnet.br</email></corresp></author-notes><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2014</year></pub-date><volume>18</volume><issue>2</issue><fpage>165</fpage><lpage>173</lpage><history><date date-type="received"><day>09</day><month>5</month><year>2013</year></date><date date-type="rev-recd"><day>20</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>02</day><month>10</month><year>2013</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited. </license-p></license></permissions><abstract><sec><title>Objective</title><p>The current study evaluated the costs and benefits of a simple aerobic
walking program for patients with chronic obstructive pulmonary disease
(COPD). </p></sec><sec><title>Method</title><p>This was a blinded randomized controlled clinical trial that recruited 72
patients diagnosed with COPD, 40 of whom were included in the study and
divided into two groups [control group (CG) and pulmonary rehabilitation
group (G<sub>PR</sub>)]. We assessed pulmonary function, distance covered
during the 6-minute walk test (6MWT), respiratory and peripheral muscle
strength, health-related quality of life (HRQOL), body composition, and
level of activities of daily living (ADLs) before and after an 8-week
walking program. The financial costs were calculated according to the
pricing table of the Brazilian Unified Health System (SUS). </p></sec><sec><title>Results</title><p>Only 34 of the 40 patients remained in the final sample; 16 in the CG and 18
in the G<sub>PR</sub> (FEV<sub>1</sub>: 50.9&#x000b1;14% predicted and
FEV<sub>1</sub>: 56&#x000b1;0.5% predicted, respectively). The intervention
group exhibited improvements in the 6MWT, sensation of dyspnea and fatigue,
work performed, BODE index (p&#x0003c;0.01), HRQOL, ADL level (p&#x0003c;0.001), and
lower limb strength (p&#x0003c;0.05). The final mean cost per patient for the
G<sub>PR</sub> was R$ 148.75 (~US$ 75.00) and no patient significantly
exceeded this value. However, 2 patients in the CG did exceed this value,
incurring a cost of R$ 689.15 (~US$ 345.00). </p></sec><sec><title>Conclusion</title><p>Aerobic walking demonstrated significant clinical benefits in a
cost-efficient manner in patients with COPD.</p></sec></abstract><kwd-group><kwd>rehabilitation</kwd><kwd>chronic obstructive pulmonary disease</kwd><kwd>exercise</kwd><kwd>health care costs</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Chronic Obstructive Pulmonary Disease (COPD) is a worldwide public health problem
characterized by chronic and progressively limited airflow that is not completely
reversible, leading to high morbidity and mortality. Dyspnea, fatigue, and chronic
cough are the most common symptoms in COPD<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. In addition to these conventional symptoms, clinical
worsening or exacerbations related to increased mortality, diminished health-related
quality of life, and a substantial r ise in sanitary and social expenses occur
during the natural history of the disease. Non-participation in pulmonary
rehabilitation programs was considered the most common risk factor in patients
hospitalized for exacerbation<sup><xref rid="r02" ref-type="bibr">2</xref></sup>.</p><p>In spite of the good results<sup><xref rid="r03" ref-type="bibr">3</xref></sup>,
multidisciplinary pulmonary rehabilitation programs are not always accessible, incur
an additional cost that may not be feasible for all patients, and exhibit low
patient adherence, resulting in benefits disappearing between 6 months and one year
after program completion<sup><xref rid="r04" ref-type="bibr">4</xref></sup>. On the
other hand, engaging in regular independent aerobic exercise for more than 4
hours/week lowers the risk of hospitalization and mortality. This effective activity
is more likely to be adhered to, is less expensive, and can be easily applied in
environments near the patients' home<sup><xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup>.</p><p>Considering the scarcity of pulmonary rehabilitation programs offered to patients
with COPD by the Unified Health System, the present study evaluated the costs and
benefits of implementing a simple aerobic walking program. We assessed clinical
findings, such as functional capacity, health-related quality of life,
exacerbations, and hospitalizations during the course of the program, as well as
quantifying the monetary costs required to develop it.</p></sec><sec sec-type="methods"><title>Method</title><p>This is a blind randomized controlled clinical trial, conducted according to
Consolidated Standards of Reporting Trials (CONSORT) guidelines<sup><xref rid="r07" ref-type="bibr">7</xref></sup>. Patients with COPD, aged 40 to 85
years and enrolled at the high-cost drug distribution center of the municipality
were recruited. The individuals were in medical follow-up, not undergoing home
oxygen therapy, free of COPD exacerbations for at least three months prior to
enrollment and had not participated in any physical activity program in the last six
months. Exclusion criteria were comorbidities that potentially interfered with gait,
a decline in peripheral oxygen saturation (SpO<sub>2</sub>) to &#x0003c;90% during the
six-minute walk test (6MWT), withdrawal from the exercise program, absence from
activity sessions more than once a week or absence from reassessment. The study was
approved by the Research Ethics Committee of Universidade Federal do Rio Grande do
Norte (UFRN), Natal, RN, Brazil, under protocol 449/2010, according to the
Declaration of Helsinki of 1975, and registered with the Brazilian Clinical Trials
Registry (RBR-7bqxm2). All of the subjects were informed of the procedures and gave
their informed written consent.</p><p>Initial evaluation was carried out by a physical therapist blinded to group
assignment. All subjects attended two educational classes on COPD and the role of
aerobic exercises in improving symptoms and activities of daily living. Next,
subjects were randomly allocated to a control group (CG) or an intervention group
(G<sub>PR</sub>) bsealed envelopes. In addition to the two educational classes,
the G<sub>PR</sub> engaged in aerobic walking for eight weeks. Both groups were
reassessed at the end of the eight weeks, as shown in the flow diagram in <xref ref-type="fig" rid="f01">Figure 1</xref>.</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow diagram.</p></caption><graphic xlink:href="rbfis-18-02-0165-g01"/></fig><sec><title>Assessment instruments and procedures</title><sec><title>Aerobic walking program</title><p>The G<sub>PR</sub> underwent an eight-week aerobic walking program with five
weekly sessions, two of which were supervised by a physical therapist. In
the initial weeks, the goal was to walk for 40 minutes and, after the fourth
week, walking time was progressively increased to 60 minutes. Supervised
activities were performed in small groups (maximum of three patients),
always interrupted whenever the sensation of dyspnea reached a score of five
(intense). Each patient received a chart to record the progress of walking
time, sensation of dyspnea, and fatigue for non-supervised activities, and
were instructed to use the modified Borg scale (0 to 10), attributing a
maximum score of 5 for interruption. The CG was not submitted to an exercise
program, but was offered the same program as the G<sub>PR</sub> after the
conclusion of the study.</p></sec><sec><title>Body composition and anthropometric assessment</title><p>Body composition was obtained by bioimpedance (Inbody R20, Biospace Co. Ltd.,
Seoul, South Korea) before and after the program, which determined fat free
mass (FFM) and skeletal muscle mass (SMM) of the limbs. For measurement, the
individual should be standing after 5 minutes of rest with an emptied
bladder and no metal objects on the body. Height was measured with a
stadiometer coupled to a Filizola PL200 anthropometric scale
(Filizola<sup>&#x000ae;</sup>, S&#x000e3;o Paulo, Brazil).</p></sec><sec><title>Spirometry and respiratory muscle strength</title><p>Spirometry was performed with the DATOSPIR-120 spirometer
(SibelMed<sup>&#x000ae;</sup>, Barcelona, Spain) following Brazilian Pneumology
Society guidelines<sup><xref rid="r08" ref-type="bibr">8</xref></sup> and
considering the predictive reference values proposed by Pereira et
al.<sup><xref rid="r09" ref-type="bibr">9</xref></sup>. Maximum
inspiratory and expiratory pressures (MIP and MEP) and sniff nasal
inspiratory pressure (SNIP) were assessed using a MicroRPM electronic
pressure transducer (Micromedical<sup>&#x000ae;</sup>, Kent, UK). Technical criteria
followed American Thoracic Society/European Respiratory Society
recommendations<sup><xref rid="r10" ref-type="bibr">10</xref></sup>.
MIP and MEP were obtained considering the maximum value reached in at most
five tests with a 1-minute rest period between tests. Values obtained for
MIP and MEP were compared with reference values for the Brazilian
population<sup><xref rid="r11" ref-type="bibr">11</xref></sup>. SNIP
was defined as the highest of 10 measurements, with a 30-second rest period
between them, according to previously described reference values<sup><xref rid="r12" ref-type="bibr">12</xref></sup>.</p></sec><sec><title>Six-minute walk test</title><p>The six-minute walk test was used to analyze exercise tolerance, in
accordance with American Thoracic Society recommendations<sup><xref rid="r13" ref-type="bibr">13</xref></sup>. The test was conducted in
a 30-meter flat corridor. Respiratory rate, heart rate, and SpO2 were
assessed before and immediately after the test, the latter two with the a
pulse oximeter, model 2500A (Nonin Medical Inc., Plymouth, MN, USA) and
blood pressure using the ML035 aneroid sphygmomanometer
(Solidor<sup>&#x000ae;</sup>, S&#x000e3;o Paulo, SP, Brazil). In addition, symptoms of
dyspnea and lower limb fatigue were assessed by the modified Borg scale. Two
tests were conducted with a 30-minute rest period between them, and the
longest distance covered was recorded. The predicted distance was calculated
using equations proposed by Iwama et al.<sup><xref rid="r14" ref-type="bibr">14</xref></sup>. Maximum work (W<sub>max</sub>) performed was
calculated with the equations proposed by Hill et al.<sup><xref rid="r15" ref-type="bibr">15</xref></sup> and Cavalheri et
al.<sup><xref rid="r16" ref-type="bibr">16</xref></sup> using body
weight and fat free mass, respectively.</p></sec><sec><title>Peripheral muscle strength</title><p>Hand-grip strength was obtained with a hand-held dynamometer on the dominant
side (Jamar<sup>&#x000ae;</sup>, Sammons Preston Inc., Bolingbrook, IL, USA). Three
reproducible tests (&#x02264;5%) were carried out, and the highest value recorded.
Lower limb strength was evaluated by a one repetition maximum test (1RM) of
the dominant side, on a leg curl machine (Studio Residencial Modelo 405,
Embreex Ind. e Com. Ltda., Brusque, SC, Brazil).</p></sec><sec><title>BODE index and health-related quality of life</title><p>The mortality index was calculated based on the Body-mass index, airflow
Obstruction, Dyspnea, and Exercise capacity (BODE) index<sup><xref rid="r17" ref-type="bibr">17</xref></sup>. Health-related quality of
life (HRQOL) was assessed using the Saint George's Respiratory Questionnaire
(SGRQ), with aspects related to three domains: symptoms, activity, and
impacts<sup><xref rid="r18" ref-type="bibr">18</xref></sup>.
Perceived dyspnea was evaluated by the Medical Research Council (MRC)
scale<sup><xref rid="r19" ref-type="bibr">19</xref></sup>. The
London Chest Activity of Daily Living (LCADL)<sup><xref rid="r20" ref-type="bibr">20</xref></sup> scale was used to determine the intensity
of perceived dyspnea in daily activities.</p></sec><sec><title>Cost calculation</title><p>Direct costs, which include those of the aerobic exercise program, were
calculated based on the value of physical therapy treatment of patients with
respiratory disease and systemic complications. The cost of each assessment
procedure was also considered. This procedure consisted of assessing body
and anthropometric composition, pulmonary function, respiratory muscle
strength, 6MWT, peripheral muscle strength, mortality index, and HRQOL. The
cost of exacerbations, hospitalizations, and increased use of medication
were calculated using the Pricing Table for Procedures, Medication,
Orthoses, Prostheses, and Special Materials (OPM, National Health
System/SUS)<sup><xref rid="r21" ref-type="bibr">21</xref></sup>. The
values of generic drugs were obtained in Brazilian currency (Reais),
according to the Ministry of Health price structure<sup><xref rid="r22" ref-type="bibr">22</xref></sup>.</p></sec><sec><title>Sample calculation and statistical analysis</title><p>The standard deviation of the 133-meter walk test from a previously published
study<sup><xref rid="r17" ref-type="bibr">17</xref></sup> was used
to obtain the total sample number. Student's t-test, an alpha error of 0.05
with bilateral distribution, and a test power of 80% were applied. The test
considered an intergroup difference of 84.48 meters, indicating a sample
size of 20 patients for treatment. The Shapiro-Wilk test was used to analyze
sample distribution, an unpaired t-test was used for intergroup comparisons
before the intervention, and two-way ANOVA (time vs. intervention) with
Bonferroni's post-hoc test was used to analyze intragroup and intergroup
differences. The GraphPad Prism 4 software (GraphPad Software Inc., San
Diego, CA, USA) was used at a significance level of 95% (p&#x0003c;0.05).</p></sec></sec></sec><sec sec-type="results"><title>Results</title><p>Forty of the 72 patients contacted agreed to take part in the study, all of whom
underwent the first assessment and attended educational classes. Two individuals
with SpO<sub>2</sub>&#x0003c;90% were excluded during the 6MWT. The sample was randomized
and patients were allocated to the CG or G<sub>PR</sub> (19 subjects in each group).
The intervention program, consisting of walks in public squares and parks in the
city, exhibited a certain limitation owing to climatic variations. However, these
variations were very small during the study period, since our city often suffers
from long periods of drought, which favored the proposed program. During the
intervention period 4 patients were excluded, 1 from the G<sub>PR</sub> who required
surgery, and 3 from the CG, 2 of whom exacerbated during the 8-week study and 1 who
did not appear for clinical reassessment. The final sample was composed of 34
patients of the total sample, 16 in the CG and 18 in the G<sub>PR</sub>, with 61.8%
having above-ideal BMI values (62.5% of the CG and 61.1% of the G<sub>PR</sub>;
<xref ref-type="table" rid="t01">Table 1</xref>).</p><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Anthropometric distribution, life habits and disease classification.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="1">Subjects</th><th rowspan="1" colspan="1">CG (n=16)</th><th rowspan="1" colspan="1">GPR (n=18)</th><th rowspan="1" colspan="1">Total (n= 34)</th><th rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td colspan="2" rowspan="1">Male/Female n (%)</td><td align="center" rowspan="1" colspan="1">6 (17.6) / 10 (29.4)</td><td align="center" rowspan="1" colspan="1">11 (32.4) / 7 (20.6)</td><td align="center" rowspan="1" colspan="1">17 (50) / 17 (50)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="2" rowspan="1">Age</td><td align="center" rowspan="1" colspan="1">70.5&#x000b1;8.1</td><td align="center" rowspan="1" colspan="1">64.6&#x000b1;10.1</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td colspan="2" rowspan="1"><italic>&#x0003c;65(years) n (%)</italic></td><td align="center" rowspan="1" colspan="1">3 (8.8)</td><td align="center" rowspan="1" colspan="1">11 (32.4)</td><td align="center" rowspan="1" colspan="1">14 (41.2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="2" rowspan="1"><italic>&#x0003e;65(years) n (%)</italic></td><td align="center" rowspan="1" colspan="1">13 (38.2)</td><td align="center" rowspan="1" colspan="1">7 (20.6)</td><td align="center" rowspan="1" colspan="1">20 (58.8)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="2" rowspan="1">BMI </td><td align="center" rowspan="1" colspan="1">26.43&#x000b1;5.31 </td><td align="center" rowspan="1" colspan="1">28.1&#x000b1;5.1</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">0.35</td></tr><tr><td colspan="2" rowspan="1"><italic>&#x0003c;21(kg/m2) n (%)</italic></td><td align="center" rowspan="1" colspan="1">2 (5.9)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">2 (6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="2" rowspan="1"><italic>&#x0003e;21(kg/m2) n (%)</italic></td><td align="center" rowspan="1" colspan="1">14 (41.1)</td><td align="center" rowspan="1" colspan="1">18 (52.9)</td><td align="center" rowspan="1" colspan="1">32 (94.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="2" rowspan="1">Current smoker &#x02013;Yes n (%)</td><td align="center" rowspan="1" colspan="1">2 (5.9)</td><td align="center" rowspan="1" colspan="1">2 (5.9)</td><td align="center" rowspan="1" colspan="1">4 (11.8)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="2" rowspan="1">Physical activity n (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">Never</td><td align="center" rowspan="1" colspan="1">9 (26.5)</td><td align="center" rowspan="1" colspan="1">8 (23.5)</td><td align="center" rowspan="1" colspan="1">17 (50)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1"><italic>Yes (stopped a long time ago)</italic></td><td align="center" rowspan="1" colspan="1">3 (8.8)</td><td align="center" rowspan="1" colspan="1">3 (8.8)</td><td align="center" rowspan="1" colspan="1">6 (17.6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1"><italic>Yes (stopped a short time ago)</italic></td><td align="center" rowspan="1" colspan="1">4 (11.8)</td><td align="center" rowspan="1" colspan="1">7 (20.6)</td><td align="center" rowspan="1" colspan="1">11 (32.4)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="2" rowspan="1">FEV<sub>1</sub> (%pred)</td><td align="center" rowspan="1" colspan="1">50.96&#x000b1;14.08</td><td align="center" rowspan="1" colspan="1">56.08&#x000b1;16.07</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">0.33</td></tr><tr><td colspan="2" rowspan="1">6MWT (meters) (%pred)</td><td align="center" rowspan="1" colspan="1">383&#x000b1;72.5 (74%)</td><td align="center" rowspan="1" colspan="1">430&#x000b1;80.6 (79%)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td colspan="2" rowspan="1">MRC</td><td align="center" rowspan="1" colspan="1">2.75&#x000b1;0.85</td><td align="center" rowspan="1" colspan="1">2.33&#x000b1;0.84</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">0.16</td></tr><tr><td colspan="2" rowspan="1">BODE </td><td align="center" rowspan="1" colspan="1">3.37&#x000b1;1.9</td><td align="center" rowspan="1" colspan="1">2.38&#x000b1;1.46 </td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">0.1</td></tr></tbody></table><table-wrap-foot><fn><p>BMI: Body mass index; FEV<sub>1</sub>: Forced expiratory volume; MRC:
Medical Research Council; BODE: Body mass index, airflow Obstruction,
Dyspnea, and Exercise capacity. Mean&#x000b1;SD. Unpaired t-test</p></fn></table-wrap-foot></table-wrap><p>Spirometry showed a chronic obstructive pattern with no post-bronchodilator
reversibility, and subjects were classified according to GOLD
recommendations<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. The CG
exhibited an FEV<sub>1</sub>/FVC of 0.60&#x000b1;0.09 and FEV<sub>1</sub> of 50.9&#x000b1;14%
predicted, and the G<sub>PR</sub> exhibited an FEV<sub>1</sub>/FVC of 0.62&#x000b1;0.08 and
FEV<sub>1</sub> of 56&#x000b1;0.5% predicted. With respect to respiratory muscle
strength, subjects in the CG demonstrated MIP, MEP, and SNIP values of 75.2&#x000b1;22.8
cmH<sub>2</sub>O (88%pred), 81&#x000b1;19.1 cmH<sub>2</sub>O (102%pred), 88&#x000b1;24.8
cmH<sub>2</sub>O (81%pred), respectively, while values in the G<sub>PR
</sub>were 92.2&#x000b1;24.2 cmH<sub>2</sub>O (86%pred), 70.3&#x000b1;14.7 cmH<sub>2</sub>O
(93%pred), and 75.6&#x000b1;16.7 cmH<sub>2</sub>O (82%pred), respectively. Initially, there
were no statistically significant intergroup differences between anthropometric and
pulmonary function values (<xref ref-type="table" rid="t01">Table 1</xref>).</p><sec><title>Effects of the aerobic exercise program</title><p>After the eight-week intervention, there was improvement in the 6MWT distance in
the G<sub>PR</sub> (&#x00394;=42.8 meters, p&#x0003c;0.01) and a significant decrease
(p&#x0003c;0.01) in the sensation of dyspnea and fatigue. The CG showed a reduction
in meters walked (&#x00394;=-51.5 meters) at follow-up. After the intervention, the
G<sub>PR</sub> achieved better BODE index scores and, although the
intervention was not aimed at improving respiratory muscle strength, there were
significant improvements in MEP and SNIP (p=0.03 and p=0.02), respectively
(<xref ref-type="table" rid="t02">Table 2</xref>).</p><table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><p>Clinical effects of the Pulmonary Rehabilitation Program.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">&#x000a0;</th><th colspan="2" rowspan="1">CG</th><th rowspan="1" colspan="1">&#x000a0;</th><th colspan="2" rowspan="1">G<sub>PR</sub></th><th rowspan="1" colspan="1">&#x000a0;</th></tr><tr><th rowspan="1" colspan="1">Initial</th><th rowspan="1" colspan="1">Final</th><th rowspan="1" colspan="1">%change</th><th rowspan="1" colspan="1">Initial</th><th rowspan="1" colspan="1">Final</th><th rowspan="1" colspan="1">%change</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Distance (6MWT)</td><td align="center" rowspan="1" colspan="1">383&#x000b1;72.5</td><td align="center" rowspan="1" colspan="1">331.8&#x000b1;86.7</td><td align="center" rowspan="1" colspan="1">&#x02013;13.6</td><td align="center" rowspan="1" colspan="1">430&#x000b1;80.6</td><td align="center" rowspan="1" colspan="1">472&#x000b1;72.7<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">9.8</td></tr><tr><td align="center" rowspan="1" colspan="1">Borg's dyspnea</td><td align="center" rowspan="1" colspan="1">2.8&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">4.1&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">46.4</td><td align="center" rowspan="1" colspan="1">2.3&#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">1.8&#x000b1;1.2<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;21.7</td></tr><tr><td align="center" rowspan="1" colspan="1">Borg's fatigue</td><td align="center" rowspan="1" colspan="1">2.6&#x000b1;2</td><td align="center" rowspan="1" colspan="1">3.7&#x000b1;1.7</td><td align="center" rowspan="1" colspan="1">42.4</td><td align="center" rowspan="1" colspan="1">1.8&#x000b1;1.6</td><td align="center" rowspan="1" colspan="1">1.7&#x000b1;1.3<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;5.5</td></tr><tr><td align="center" rowspan="1" colspan="1">Wmax (Kg x m)</td><td align="center" rowspan="1" colspan="1">24.8&#x000b1;8.2</td><td align="center" rowspan="1" colspan="1">21.3&#x000b1;8</td><td align="center" rowspan="1" colspan="1">&#x02013;13.9</td><td align="center" rowspan="1" colspan="1">31&#x000b1;10.7</td><td align="center" rowspan="1" colspan="1">34.2&#x000b1;10<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">10.3</td></tr><tr><td align="center" rowspan="1" colspan="1">Wmax (FFM x m)</td><td align="center" rowspan="1" colspan="1">14.8&#x000b1;5.2</td><td align="center" rowspan="1" colspan="1">12.4&#x000b1;4.6</td><td align="center" rowspan="1" colspan="1">&#x02013;16.2</td><td align="center" rowspan="1" colspan="1">18.4&#x000b1;5.2</td><td align="center" rowspan="1" colspan="1">21.3&#x000b1;5.2<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">15.8</td></tr><tr><td align="center" rowspan="1" colspan="1">MRC</td><td align="center" rowspan="1" colspan="1">2.8&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">3.3&#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">17.9</td><td align="center" rowspan="1" colspan="1">2.3&#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">2&#x000b1;0.6<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;13.0</td></tr><tr><td align="center" rowspan="1" colspan="1">BODE</td><td align="center" rowspan="1" colspan="1">3.4&#x000b1;2</td><td align="center" rowspan="1" colspan="1">4.8 &#x000b1;1.7</td><td align="center" rowspan="1" colspan="1">41.4</td><td align="center" rowspan="1" colspan="1">2.4&#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">1.9&#x000b1;1.3<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;20.5</td></tr><tr><td align="center" rowspan="1" colspan="1">MEP (cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">88&#x000b1;25</td><td align="center" rowspan="1" colspan="1">82&#x000b1;24.2</td><td align="center" rowspan="1" colspan="1">&#x02013;6.8</td><td align="center" rowspan="1" colspan="1">92.1&#x000b1;23.5</td><td align="center" rowspan="1" colspan="1">103&#x000b1;24.1<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">11.9</td></tr><tr><td align="center" rowspan="1" colspan="1">SNIP (cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">70.3&#x000b1;14.7</td><td align="center" rowspan="1" colspan="1">63.3&#x000b1;12.4</td><td align="center" rowspan="1" colspan="1">&#x02013;9.9</td><td align="center" rowspan="1" colspan="1">75.6&#x000b1;16.3</td><td align="center" rowspan="1" colspan="1">77&#x000b1;18.8<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">1.9</td></tr><tr><td align="center" rowspan="1" colspan="1">SGRQ (total)</td><td align="center" rowspan="1" colspan="1">55&#x000b1;17</td><td align="center" rowspan="1" colspan="1">64.3&#x000b1;12</td><td align="center" rowspan="1" colspan="1">16.9</td><td align="center" rowspan="1" colspan="1">42.8&#x000b1;14.7</td><td align="center" rowspan="1" colspan="1">26.4&#x000b1;7.3<xref ref-type="table-fn" rid="tfn01t02">*</xref><xref ref-type="table-fn" rid="tfn02t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;38.5</td></tr><tr><td align="center" rowspan="1" colspan="1">SGRQ (symptoms)</td><td align="center" rowspan="1" colspan="1">58.3&#x000b1;15.5</td><td align="center" rowspan="1" colspan="1">61&#x000b1;14.1</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">41.6&#x000b1;19.3</td><td align="center" rowspan="1" colspan="1">25&#x000b1;12.5<xref ref-type="table-fn" rid="tfn01t02">*</xref><xref ref-type="table-fn" rid="tfn02t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;40.0</td></tr><tr><td align="center" rowspan="1" colspan="1">SGRQ (activity)</td><td align="center" rowspan="1" colspan="1">64.8&#x000b1;16.5</td><td align="center" rowspan="1" colspan="1">76.5&#x000b1;11.7</td><td align="center" rowspan="1" colspan="1">18.1</td><td align="center" rowspan="1" colspan="1">56&#x000b1;16.8</td><td align="center" rowspan="1" colspan="1">36.5&#x000b1;9<xref ref-type="table-fn" rid="tfn01t02">*</xref><xref ref-type="table-fn" rid="tfn02t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;34.8</td></tr><tr><td align="center" rowspan="1" colspan="1">SGRQ (impacts)</td><td align="center" rowspan="1" colspan="1">47.3&#x000b1;20.5</td><td align="center" rowspan="1" colspan="1">58.2&#x000b1;17.3</td><td align="center" rowspan="1" colspan="1">23.0</td><td align="center" rowspan="1" colspan="1">35.7&#x000b1;16.3</td><td align="center" rowspan="1" colspan="1">21.1&#x000b1;7.8<xref ref-type="table-fn" rid="tfn01t02">*</xref><xref ref-type="table-fn" rid="tfn02t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;40.9</td></tr><tr><td align="center" rowspan="1" colspan="1">LCADL (total)</td><td align="center" rowspan="1" colspan="1">29.8&#x000b1;7.7</td><td align="center" rowspan="1" colspan="1">36.2&#x000b1;8.5</td><td align="center" rowspan="1" colspan="1">21.5</td><td align="center" rowspan="1" colspan="1">30.5&#x000b1;7.4</td><td align="center" rowspan="1" colspan="1">24.1&#x000b1;5.1<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;21.1</td></tr><tr><td align="center" rowspan="1" colspan="1">LCADL (personal care)</td><td align="center" rowspan="1" colspan="1">23.8&#x000b1;6.5</td><td align="center" rowspan="1" colspan="1">29.1&#x000b1;5.2</td><td align="center" rowspan="1" colspan="1">22.3</td><td align="center" rowspan="1" colspan="1">27.2&#x000b1;5.3</td><td align="center" rowspan="1" colspan="1">21.4&#x000b1;2.5</td><td align="center" rowspan="1" colspan="1">&#x02013;21.3</td></tr><tr><td align="center" rowspan="1" colspan="1">LCADL (domestic activity)</td><td align="center" rowspan="1" colspan="1">22.1&#x000b1;19.4</td><td align="center" rowspan="1" colspan="1">28.2&#x000b1;22.9</td><td align="center" rowspan="1" colspan="1">27.5</td><td align="center" rowspan="1" colspan="1">19.3&#x000b1;17.2</td><td align="center" rowspan="1" colspan="1">13&#x000b1;11.5<xref ref-type="table-fn" rid="tfn01t02">*</xref><xref ref-type="table-fn" rid="tfn02t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;40.5</td></tr><tr><td align="center" rowspan="1" colspan="1">LCADL (physical activity)</td><td align="center" rowspan="1" colspan="1">37.5&#x000b1;11.8</td><td align="center" rowspan="1" colspan="1">50.6&#x000b1;11.2</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">37.2&#x000b1;11</td><td align="center" rowspan="1" colspan="1">27.2&#x000b1;8<xref ref-type="table-fn" rid="tfn01t02">*</xref><xref ref-type="table-fn" rid="tfn02t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">&#x02013;26.9</td></tr><tr><td align="center" rowspan="1" colspan="1">LCADL (leisure)</td><td align="center" rowspan="1" colspan="1">25&#x000b1;6.7</td><td align="center" rowspan="1" colspan="1">26.3&#x000b1;7.1</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">25.9&#x000b1;7</td><td align="center" rowspan="1" colspan="1">20.4&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">&#x02013;21.3</td></tr><tr><td align="center" rowspan="1" colspan="1">1 RM</td><td align="center" rowspan="1" colspan="1">9.9&#x000b1;5</td><td align="center" rowspan="1" colspan="1">9.3&#x000b1;6</td><td align="center" rowspan="1" colspan="1">6.1</td><td align="center" rowspan="1" colspan="1">8.8&#x000b1;3.3</td><td align="center" rowspan="1" colspan="1">13.2&#x000b1;4.4<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">50.0</td></tr><tr><td align="center" rowspan="1" colspan="1">SMM (LRL)</td><td align="center" rowspan="1" colspan="1">5.3&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">5.1&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">&#x02013;3.7</td><td align="center" rowspan="1" colspan="1">6&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">6.5&#x000b1;1.5<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">8.5</td></tr><tr><td align="center" rowspan="1" colspan="1">SMM (LLL)</td><td align="center" rowspan="1" colspan="1">5.3 &#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">5.1&#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">&#x02013;3.7</td><td align="center" rowspan="1" colspan="1">6&#x000b1;1.34</td><td align="center" rowspan="1" colspan="1">6.5 &#x000b1;1.5<xref ref-type="table-fn" rid="tfn01t02">*</xref></td><td align="center" rowspan="1" colspan="1">8.5</td></tr></tbody></table><table-wrap-foot><fn id="tfn01t02"><label>*</label><p>p&#x0003c;0.05;</p></fn><fn id="tfn02t02"><label>&#x02020;</label><p>- ANOVA with Bonferroni's post-test</p></fn><fn><p>6MWT: 6-minute walk test (meters); Wmax: maximum work; FFM: fat free
mass; MEP: maximum expiratory pressure; SNIP: sniff nasal
inspiratory pressure; MRC: Medical Research Council; BODE: Body mass
index, airflow Obstruction, Dyspnea, and Exercise capacity; SGRQ:
Saint George's Respiratory Questionnaire; LCADL: London Chest
Activity of Daily Living; 1RM: 1 repetition maximum; SMM: skeletal
muscle mass; LRL: lower right limb; LLL: Lower left limb</p></fn></table-wrap-foot></table-wrap><p>HRQOL exhibited significantly different intergroup scores after the intervention
period in the domains symptoms, activity, and impacts. Hand-grip strength did
not change after the intervention (CG: 23&#x000b1;8.6 vs. 23.1&#x000b1;8 and G<sub>PR</sub>
30.7&#x000b1;8.2 vs. 30.6&#x000b1;6.8). Muscle strength in the lower limbs improved
significantly (p&#x0003c;0.05), as did muscle mass (<xref ref-type="table" rid="t02">Table 2</xref>).</p></sec><sec><title>Costs of the aerobic exercise program</title><p>Calculations of the direct costs of the program are presented in Brazilian Reais
(R$) for each procedure. It is important to underscore that 37 patients were
assessed by bioimpedance, even though the Unified Health System (SUS) price
structure does not include this examination. The costs incurred for spirometry,
6MWT, assessment of respiratory mechanics (spirometry and maximum respiratory
pressures), and peripheral muscle function were R$6.36, R$2.78, R$10.00, and
R$1.26, with a total individual assessment cost of R$20.40.</p><p>In cost analysis for each group, costs related to educational classes and
physical therapy supervision during walking activities were added, both with
individual values of R$6.35. Walks were performed with professional supervision
twice a week, for 8 weeks (18 sessions), for a total of R$101.60/person. The
G<sub>PR</sub> underwent 288 exercise sessions, with a total cost for the CG
and G<sub>PR</sub> of R$1,575.49 and R$2,731.00, respectively. Individual costs
of patients with COPD in the public health system, with and without walking
intervention, demonstrate that subjects who did not participate in the
intervention and consequently exacerbated, could incur a higher individual cost
for the public health system, estimated to be 46.33% higher (<xref ref-type="table" rid="t03">Table 3</xref>). Costs related to the type of
care received, number of days hospitalized, costs of procedures, and medication
due to exacerbation were calculated according to generic drug prices,
considering the type of treatment received and number of days hospitalized in
patients who exacerbated (<xref ref-type="table" rid="t04">Table 4</xref>). Two
subjects in the CG experienced exacerbations, leading to a total cost of care
being substantially higher compared to the G<sub>PR</sub>.</p><table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><p>Individual cost of a patient with COPD: without Pulmonary Rehabilitation
and with Pulmonary Rehabilitation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">COPD without PR (R$)<xref ref-type="table-fn" rid="tfn03t03">***</xref></th><th rowspan="1" colspan="1">COPD with PR (R$)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Initial assessment</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">20.40</td></tr><tr><td align="center" rowspan="1" colspan="1">Educational class</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">6.35</td></tr><tr><td align="center" rowspan="1" colspan="1">Supervised training </td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">101.60</td></tr><tr><td align="center" rowspan="1" colspan="1">Reassessment</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">20.40</td></tr><tr><td align="center" rowspan="1" colspan="1">Emergency treatment<xref ref-type="table-fn" rid="tfn01t03">*</xref></td><td align="center" rowspan="1" colspan="1">12.47</td><td align="center" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" rowspan="1" colspan="1">Hospitalization<xref ref-type="table-fn" rid="tfn02t03">**</xref></td><td align="center" rowspan="1" colspan="1">676.68</td><td align="center" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">689.15</td><td align="center" rowspan="1" colspan="1">148.75</td></tr></tbody></table><table-wrap-foot><fn><p>R$ - Value in Brazilian Reais</p></fn><fn id="tfn01t03"><label>*</label><p>Price structure of procedures and Orthoses, Prostheses and Materials
(OPM) (SUS): Medication, Orthoses, Prostheses and Special Materials
of the Unified Health System (SUS)</p></fn><fn id="tfn02t03"><label>**</label><p>Mean hospitalization costs in the Unified Health System (Source:
<ext-link ext-link-type="uri" xlink:href="http://tabnet.datasus.gov.br/cgi/deftohtm.exe?idb2011/e11.def">tabnet.datasus.gov.br/cgi/deftohtm.exe?idb2011/e11.def</ext-link>)</p></fn><fn id="tfn03t03"><label>***</label><p>R$1.00 ~ US$0.50.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t04" orientation="portrait" position="float"><label>Table 4</label><caption><p>Total costs for the control and intervention group calculated according
to the Unified Health System (SUS) Price structure<sup>21</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Control Group (R$)</th><th rowspan="1" colspan="1">Intervention Group (R$)</th><th rowspan="1" colspan="1">Total Cost</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Initial assessment</td><td align="center" rowspan="1" colspan="1">408.00</td><td align="center" rowspan="1" colspan="1">408.00</td><td align="center" rowspan="1" colspan="1">816.00</td></tr><tr><td align="center" rowspan="1" colspan="1">Educational classes</td><td align="center" rowspan="1" colspan="1">127.00</td><td align="center" rowspan="1" colspan="1">127.00</td><td align="center" rowspan="1" colspan="1">254.00</td></tr><tr><td align="center" rowspan="1" colspan="1">Supervised Training</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">1,828.80</td><td align="center" rowspan="1" colspan="1">1,828.80</td></tr><tr><td align="center" rowspan="1" colspan="1">Reassessment</td><td align="center" rowspan="1" colspan="1">326.40</td><td align="center" rowspan="1" colspan="1">367.20</td><td align="center" rowspan="1" colspan="1">693.60</td></tr><tr><td align="center" rowspan="1" colspan="1">Emergency treatment<xref ref-type="table-fn" rid="tfn01t04">*</xref></td><td align="center" rowspan="1" colspan="1">37.41</td><td align="center" rowspan="1" colspan="1">-----</td><td align="center" rowspan="1" colspan="1">37.41</td></tr><tr><td align="center" rowspan="1" colspan="1">Hospitalization<xref ref-type="table-fn" rid="tfn02t04">**</xref></td><td align="center" rowspan="1" colspan="1">676.68</td><td align="center" rowspan="1" colspan="1">-----</td><td align="center" rowspan="1" colspan="1">676.68</td></tr><tr><td align="center" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">1,575.49</td><td align="center" rowspan="1" colspan="1">2,731.00</td><td align="center" rowspan="1" colspan="1">4,306.49</td></tr><tr><td colspan="4" style="border-bottom:thin solid" align="center" rowspan="1">COSTS OF EXACERBATIONS ACCORDING TO TREATMENT RECEIVED:
INCURRED BY SUBJECTS IN CONTROL GROUP ONLY</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>EXACERBATION</bold></td><td align="center" rowspan="1" colspan="1"><bold>Outpatient Treatment</bold></td><td align="center" rowspan="1" colspan="1"><bold>Hospital Treatment</bold></td><td align="center" rowspan="1" colspan="1"><bold>Total</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">No.</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">Emergency room treatment</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1">Days hospitalized</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="center" rowspan="1" colspan="1">Cost of medication (BRL)</td><td align="center" rowspan="1" colspan="1">466.87</td><td align="center" rowspan="1" colspan="1">1,832.05</td><td align="center" rowspan="1" colspan="1">2,298.92</td></tr><tr><td align="center" rowspan="1" colspan="1">Cost of hospital services (BRL)</td><td align="center" rowspan="1" colspan="1">24.94</td><td align="center" rowspan="1" colspan="1">689.15</td><td align="center" rowspan="1" colspan="1">714.09</td></tr><tr><td align="center" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">491.81</td><td align="center" rowspan="1" colspan="1">2,521.20</td><td align="center" rowspan="1" colspan="1">3,013.01</td></tr></tbody></table><table-wrap-foot><fn><p>R$- Value in Brazilian Reais</p></fn><fn id="tfn01t04"><label>*</label><p>Price structure of procedures and Orthoses, Prostheses and Materials
(OPM) (SUS): Medication, Orthoses, Prostheses and Special Materials
of the Unified Health System (SUS); Values of generic drugs in
Brazilian Reais (R$)</p></fn><fn id="tfn02t04"><label>**</label><p>Mean hospitalization costs in the Unified Health System (Source:
<ext-link ext-link-type="uri" xlink:href="http://www.tabnet.datasus.gov.br/cgi/deftohtm.exe?idb2011/e11.def">tabnet.datasus.gov.br/cgi/deftohtm.exe?idb2011/e11.def</ext-link>)</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The aim of the present study was to determine the costs and benefits of an aerobic
exercise walking program, conducted at primary care centers for patients with COPD.
After the program, subjects exhibited greater tolerance to exercise, reduced
symptoms, increased muscle strength and lower limb skeletal muscle mass, enhanced
HRQOL, and a higher level of daily aerobic exercise. Moreover, there was a reduction
in sanitary costs for the G<sub>PR</sub> compared to the CG.</p><p>Among the lifestyle interventions proposed for patients with COPD, there is
convincing evidence that aerobic-based physical exercises provide important clinical
benefits. The updated COPD clinical practice guidelines of the National Institute
for Health and Clinical Excellence (NICE) emphasize the benefits of exercise and
recommend it to all patients with this diagnosis<sup><xref rid="r23" ref-type="bibr">23</xref></sup>. The guide strongly suggests the practice of daily aerobic
exercises in order to minimize the number of exacerbations and
hospitalizations<sup><xref rid="r23" ref-type="bibr">23</xref></sup>. In the
present study, the aerobic exercise program, composed simply of two initial
educational classes and walking in public areas 5 times a week (2 of which were
supervised by physical therapists) for 8 weeks, resulted in significant clinical
benefits. The program demonstrated that, due to good adherence, the program
contributed to the results obtained in this study, given its easy accessibility and
low cost. Costs may be further reduced if, after a few weeks, supervised sessions
are reduced to once a week.</p><p>Clinically, aerobic exercise caused greater tolerance to exercise, as evidenced by
the 6MWT. The improvement occurred due to a combination of increased strength and
peripheral muscle endurance, which could be explained by enhanced muscle oxidative
capacity or positive adaptations in the ventilatory pattern during
exercise<sup><xref rid="r24" ref-type="bibr">24</xref></sup>. The present
study showed a mean increase of 42 meters in the 6MWT (&#x00394;=10%) in the G<sub>PR
</sub>possibly due to the walking intervention, while CG patients exhibited a
reduction of 52.8 meters (&#x00394;=13%), since 2 subjects in that group exacerbated.
Furthermore, we observed a significant decline in the sensation of dyspnea and
fatigue reported at the end of the program only in the G<sub>PR</sub>. These
findings are consistent with previous studies employing more conventional pulmonary
rehabilitation programs<sup><xref rid="r03" ref-type="bibr">3</xref></sup>.</p><p>Despite using a simple aerobic exercise program, the present study found similar
responses to those reported by other authors who assessed more structured
programs<sup><xref rid="r25" ref-type="bibr">25</xref></sup>. It is
important to underscore that structured, traditional pulmonary rehabilitation
programs are more costly, since they involve a large number of professionals, are
conducted over a longer period of time, and mostly in secondary or tertiary
hospitals far from patients' homes<sup><xref rid="r26" ref-type="bibr">26</xref></sup>. The therapeutic modality used in the present investigation
promoted an increase in lower limb peripheral muscle strength, combined with gains
in skeletal muscle mass (SMM) in both limbs. Another important aspect of the program
was its capacity to potentially lower the mortality risk (BODE) through consecutive
improvements in exercise capacity and dyspnea. Therefore walking, the primary
therapeutic modality in the program, is a safe, comfortable, and low-cost method
that provides important clinical benefits. Given the quality of the therapeutic
modality applied, we observed that the program used in the present study could be
easily reproduced by the Public Health System in primary care centers, representing
an important and effective low-cost strategy.</p><p>In relation to complications, 2 CG patients deteriorated during the study period.
Exacerbations have a negative impact on the respiratory system, which can influence
the trajectory of the disease. These clinical declines are related to increased
mortality and reduced HRQOL<sup><xref rid="r02" ref-type="bibr">2</xref></sup>.
Estimated costs of treating exacerbations, including emergency care and
hospitalizations, were added to CG costs. Thus, while the GPR incurred a higher
initial cost, avoidance of exacerbations resulted in a substantially lower ultimate
cost of care compared to the CG. Exacerbations and hospitalizations are the major
determinants of sanitary costs in COPD<sup><xref rid="r27" ref-type="bibr">27</xref></sup>. Data from the USA estimated that COPD mean annual costs per
patient were US$1,522.00, 17.3% of which was spent on medical consultations and
emergency treatment<sup><xref rid="r28" ref-type="bibr">28</xref></sup>. Another
study carried out in Canada<sup><xref rid="r29" ref-type="bibr">29</xref></sup>
found fewer hospitalizations and emergency room visits, due to the practice of
domiciliary non-supervised aerobic exercises on a bicycle ergometer, coupled with a
disease management education program. This study estimated a mean annual saving of
US$ 2,300.00 per patient.</p><p>To the best of our knowledge, no other studies have been published regarding the
costs of any type of rehabilitation program for the COPD population in Brazil. The
results presented here demonstrate an increase in medication costs caused by the
high cost of exacerbation in the CG. Despite the short follow-up period regarding
the results obtained for exacerbation costs, we can hypothesize that it would be
economically feasible and beneficial to implement simple, cost-efficient aerobic
exercise walking programs for patients with COPD. Studies have demonstrated that the
costs of exacerbation account for 40-79% of total direct costs in individuals with
COPD<sup><xref rid="r30" ref-type="bibr">30</xref></sup>. As such,
implementing proven interventions directed toward reducing such costs is highly
advantageous.</p><p>The present study exhibits a potential limitation, despite its functional relevance
with respect to HRQOL and possible financial ramifications of the interventions
applied. Specifically, conducting training activities with walking in public areas
was considered the main limitation, in light of possible climatic alterations that
may occur and restricted times to conduct the activities. However, this limitation
is related to the methodological design of the research, aimed at providing patients
with an accessible intervention. Rectifying this limitation using other, more
environmentally predictable, exercise environments, would rectify this issue and
likely produce similar benefits. Furthermore, another limitation was the sample loss
by exacerbations, surgery, desaturation, and withdrawal from the program, which
turned out to be a selection bias.</p><p>A simple rehabilitation program, consisting of two educational sessions and an
eight-week aerobic walking program applied at primary care centers for COPD,
demonstrated significant clinical benefits and economic feasibility for possible
large-scale implementation. It is therefore considered important to promote public
policies to implement low-complexity programs for these patients, especially in the
family health programs of our country.</p></sec></body><back><ref-list><title>References</title><ref id="r01"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rodriguez-Roisin</surname><given-names>R</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Bourbeau</surname><given-names>J</given-names></name><name><surname>De Guia</surname><given-names>TS</given-names></name><name><surname>Hui</surname><given-names>DSC</given-names></name><name><surname>Jenkins</surname><given-names>C</given-names></name><etal>et al</etal></person-group><etal>et al</etal><source>GOLD - Global strategy for the diagnosis, management and prevention of
chronic obstructive pulmonary disease</source><year>2011</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.org/uploads/users/files/GOLDReport_April12011.pdf">http://www.goldcopd.org/uploads/users/files/GOLDReport_April12011.pdf</ext-link></comment></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Aymerich</surname><given-names>J</given-names></name><name><surname>Lange</surname><given-names>P</given-names></name><name><surname>Benet</surname><given-names>M</given-names></name><name><surname>Schnohr</surname><given-names>P</given-names></name><name><surname>Ant&#x000f3; J</surname><given-names>M</given-names></name></person-group><article-title>Regular physical activity reduces hospital admission and
mortality in chronic obstructive pulmonary disease: a population based
cohort study</article-title><source>Thorax</source><year>2006</year><volume>61</volume><fpage>772</fpage><lpage>778</lpage><!--<pub-id pub-id-type="pmcid">PMC2117100</pub-id>--><pub-id pub-id-type="pmid">16738033</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wehrmeister</surname><given-names>FC</given-names></name><name><surname>Knorst</surname><given-names>M</given-names></name><name><surname>Jardim</surname><given-names>JR</given-names></name><name><surname>Macedo</surname><given-names>EC</given-names></name><name><surname>Noal</surname><given-names>RB</given-names></name><name><surname>Mart&#x000ed;nez-Mesa</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Pulmonary rehabilitation programs for patients with
COPD</article-title><source>J Bras Pneumol</source><year>2011</year><volume>37</volume><issue>4</issue><fpage>544</fpage><lpage>555</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1806-37132011000400017">http://dx.doi.org/10.1590/S1806-37132011000400017</ext-link><pub-id pub-id-type="pmid">21881745</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>C</given-names></name><name><surname>Deering</surname><given-names>BM</given-names></name><name><surname>Blake</surname><given-names>C</given-names></name><name><surname>Fullen</surname><given-names>BM</given-names></name><name><surname>McCormack</surname><given-names>NM</given-names></name><name><surname>Spruit</surname><given-names>MA</given-names></name><etal>et al</etal></person-group><article-title>Short term and long term effects of pulmonary rehabilitation on
physical activity in COPD</article-title><source>Respir Med</source><year>2012</year><volume>106</volume><issue>12</issue><fpage>1671</fpage><lpage>1679</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.rmed.2012.08.016">http://dx.doi.org/10.1016/j.rmed.2012.08.016</ext-link><pub-id pub-id-type="pmid">23063203</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sindhwani</surname><given-names>G</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Biswas</surname><given-names>D</given-names></name><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Rawat</surname><given-names>J</given-names></name></person-group><article-title>A pilot study on domiciliary pulmonary rehabilitation programme
in the management of severe chronic obstructive pulmonary
disease</article-title><source>Singapore Med J</source><year>2011</year><volume>52</volume><issue>9</issue><fpage>689</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">21947149</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puhan</surname><given-names>MA</given-names></name><name><surname>Scharplatz</surname><given-names>M</given-names></name><name><surname>Troosters</surname><given-names>T</given-names></name><name><surname>Steurer</surname><given-names>J</given-names></name></person-group><article-title>Respiratory rehabilitation after acute exacerbation of COPD may
reduce risk for readmission and mortality-a systematic
review</article-title><source>Respir Res</source><year>2005</year><volume>8</volume><issue>6</issue><fpage>54</fpage><lpage>54</lpage><!--<pub-id pub-id-type="pmcid">PMC1164434</pub-id>--><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1465-9921-6-54">http://dx.doi.org/10.1186/1465-9921-6-54</ext-link><pub-id pub-id-type="pmid">15943867</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><collab>CONSORT Group</collab></person-group><article-title>CONSORT 2010 Statement: updated guidelines for reporting parallel
group randomized trials</article-title><source>Open Med</source><year>2010</year><volume>4</volume><issue>1</issue><fpage>60</fpage></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Sociedade Brasileira de Pneumologia e Tisiologia</collab></person-group><article-title xml:lang="pt">Diretrizes para Testes de Fun&#x000e7;&#x000e3;o
Pulmonar</article-title><source>J Bras Pneumol</source><year>2002</year><volume>28</volume><fpage>1</fpage><lpage>221</lpage></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>CAC</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Rodrigues</surname><given-names>SC</given-names></name></person-group><article-title xml:lang="pt"> Novos valores de refer&#x000ea;ncia pra espirometria
for&#x000e7;ada em brasileiros adultos de ra&#x000e7;a branca</article-title><source>J Bras Pneumol</source><year>2007</year><volume>33</volume><issue>4</issue><fpage>397</fpage><lpage>406</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1806-37132007000400008">http://dx.doi.org/10.1590/S1806-37132007000400008</ext-link><pub-id pub-id-type="pmid">17982531</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Thoracic Society, European Respiraory Society</collab></person-group><article-title>ATS/ERS. Statement on respiratory muscle testing</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><fpage>518</fpage><lpage>624</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.166.4.518">http://dx.doi.org/10.1164/rccm.166.4.518</ext-link><pub-id pub-id-type="pmid">12186831</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neder</surname><given-names>JA</given-names></name><name><surname>Andreoni</surname><given-names>S</given-names></name><name><surname>Lerario</surname><given-names>MC</given-names></name><name><surname>Nery</surname><given-names>LE</given-names></name></person-group><article-title>References values for lung fucntion tests. Maximal respiratory
pressures and voluntary ventilation</article-title><source>Braz J Med Biol Res</source><year>1999</year><volume>32</volume><fpage>719</fpage><lpage>727</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S0100-879X1999000600007">http://dx.doi.org/10.1590/S0100-879X1999000600007</ext-link><pub-id pub-id-type="pmid">10412550</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ara&#x000fa;jo</surname><given-names>PRS</given-names></name><name><surname>Resqueti</surname><given-names>VR</given-names></name><name><surname>Nascimento J</surname><given-names>Jr</given-names></name><name><surname>Carvalho</surname><given-names>LA</given-names></name><name><surname>Cavalcanti</surname><given-names>AGL</given-names></name><name><surname>Silva</surname><given-names>VC</given-names></name><etal>et al</etal></person-group><article-title xml:lang="pt"> Valores de refer&#x000ea;ncia da press&#x000e3;o inspirat&#x000f3;ria
nasal em indiv&#x000ed;duos saud&#x000e1;veis no Brasil: estudo
multic&#x000ea;ntrico</article-title><source>J Bras Pneumol</source><year>2012</year><volume>38</volume><issue>6</issue><fpage>700</fpage><lpage>707</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1806-37132012000600004">http://dx.doi.org/10.1590/S1806-37132012000600004</ext-link><pub-id pub-id-type="pmid">23288114</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab> American Thoracic Society</collab></person-group><article-title>ATS statement: guidelines for six minute walk
test</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><fpage>111</fpage><lpage>117</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/ajrccm.166.1.at1102">http://dx.doi.org/10.1164/ajrccm.166.1.at1102</ext-link><pub-id pub-id-type="pmid">12091180</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwama</surname><given-names>AM</given-names></name><name><surname>Andrade</surname><given-names>GN</given-names></name><name><surname>Shima</surname><given-names>P</given-names></name><name><surname>Tanni</surname><given-names>SE</given-names></name><name><surname>Godoy</surname><given-names>I</given-names></name><name><surname>Dourado</surname><given-names>VZ</given-names></name></person-group><article-title>The six-minute walk test and body weight-walk distance product in
healthy Brazilian subjects</article-title><source>Braz J Med Biol Res</source><year>2009</year><volume>42</volume><fpage>1080</fpage><lpage>1085</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S0100-879X2009005000032">http://dx.doi.org/10.1590/S0100-879X2009005000032</ext-link><pub-id pub-id-type="pmid">19802464</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>K</given-names></name><name><surname>Jenkins</surname><given-names>SC</given-names></name><name><surname>Cecins</surname><given-names>N</given-names></name><name><surname>Philippe</surname><given-names>DL</given-names></name><name><surname>Hillman</surname><given-names>DR</given-names></name><name><surname>Eastwood</surname><given-names>PR</given-names></name></person-group><article-title>Estimating maximum work rate during incremental cycle ergometry
testing from six-minute walk distance in patients with chronic obstructive
pulmonary disease</article-title><source>Arch Phys Med Rehabil</source><year>2008</year><volume>89</volume><fpage>1782</fpage><lpage>1787</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.apmr.2008.01.020">http://dx.doi.org/10.1016/j.apmr.2008.01.020</ext-link><pub-id pub-id-type="pmid">18760164</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalheri</surname><given-names>V</given-names></name><name><surname>Hernandes</surname><given-names>NA</given-names></name><name><surname>Camillo</surname><given-names>CA</given-names></name><name><surname>Probst</surname><given-names>VS</given-names></name><name><surname>Ramos</surname><given-names>D</given-names></name><name><surname>Pitta</surname><given-names>F</given-names></name></person-group><article-title>Estimation of Maximal Work Rate Based on the 6-Minute Walk Test
and Fat-Free Mass in Chronic Obstructive Pulmonary Disease</article-title><source>Arch Phys Med Rehabil</source><year>2010</year><volume>91</volume><issue>10</issue><fpage>1626</fpage><lpage>1628</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.apmr.2010.07.002">http://dx.doi.org/10.1016/j.apmr.2010.07.002</ext-link><pub-id pub-id-type="pmid">20875524</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>BR</given-names></name><name><surname>Cote</surname><given-names>CG</given-names></name><name><surname>Marin</surname><given-names>JM</given-names></name><name><surname>Casanova</surname><given-names>C</given-names></name><name><surname>Montes de Oca</surname><given-names>M</given-names></name><name><surname>Mendez</surname><given-names>RA</given-names></name><etal>et al</etal></person-group><article-title>The body-mass index, airflow obstruction, dyspnea, and exercise
capacity index in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><issue>10</issue><fpage>1005</fpage><lpage>1012</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa021322">http://dx.doi.org/10.1056/NEJMoa021322</ext-link><pub-id pub-id-type="pmid">14999112</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>TC</given-names></name><name><surname>Jardim</surname><given-names>JR</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name></person-group><article-title>Valida&#x000e7;&#x000e3;o do Question&#x000e1;rio do Hospital Saint George na doen&#x000e7;a
respirat&#x000f3;ria (SGRQ) em pacientes portadores de doen&#x000e7;a pulmonar obstrutiva
cr&#x000f4;nica no Brasil</article-title><source>J Bras Pneumol</source><year>2000</year><volume>26</volume><issue>3</issue><fpage>119</fpage><lpage>128</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S0102-35862000000300004">http://dx.doi.org/10.1590/S0102-35862000000300004</ext-link></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovelis</surname><given-names>D</given-names></name><name><surname>Segretti</surname><given-names>NO</given-names></name><name><surname>Probst</surname><given-names>VS</given-names></name><name><surname>Laureau</surname><given-names>SC</given-names></name><name><surname>Brunetto</surname><given-names>AF</given-names></name><name><surname>Pitta</surname><given-names>F</given-names></name></person-group><article-title xml:lang="pt"> Valida&#x000e7;&#x000e3;o do Modified Pulmonary Functional Status
and Dyspnea Questionnaire e da escala do Medical Research Council para o uso
em pacientes com doen&#x000e7;a pulmonar obstrutiva cr&#x000f4;nica no
Brasil</article-title><source>J Bras Pneumol</source><year>2008</year><volume>34</volume><issue>12</issue><fpage>1008</fpage><lpage>1018</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1806-37132008001200005">http://dx.doi.org/10.1590/S1806-37132008001200005</ext-link><pub-id pub-id-type="pmid">19180335</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpes</surname><given-names>MF</given-names></name><name><surname>Mayer</surname><given-names>AF</given-names></name><name><surname>Simon</surname><given-names>KM</given-names></name><name><surname>Jardim</surname><given-names>JR</given-names></name><name><surname>Garrod</surname><given-names>R</given-names></name></person-group><article-title>The Brazilian Portuguese version of the London Chest Activity of
Daily Living scale for use in patients with chronic obstructive pulmonary
disease</article-title><source>J Bras Pneumol</source><year>2008</year><volume>34</volume><issue>3</issue><fpage>143</fpage><lpage>151</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1806-37132008000300004">http://dx.doi.org/10.1590/S1806-37132008000300004</ext-link><pub-id pub-id-type="pmid">18392462</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Brasil</collab><collab>Minist&#x000e9;rio da Sa&#x000fa;de</collab></person-group><source xml:lang="pt">Tabela de Procedimentos, Medicamentos, &#x000d2;rteses, Pr&#x000f3;teses e
Materiais Especiais (OPM) do Sistema &#x000da;nico de Sa&#x000fa;de - SIGTAP. Portaria n&#x000ba;
2.848</source><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name><year>2007</year></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Brasil</collab><collab>Minist&#x000e9;rio da Sa&#x000fa;de</collab></person-group><source xml:lang="pt">Lei n&#x000ba; 9.787, de 10 de fevereiro de 1999. Disp&#x000f5;e sobre a
vigil&#x000e2;ncia sanit&#x000e1;ria, estabelece o medicamento gen&#x000e9;rico, disp&#x000f5;e sobre a
utiliza&#x000e7;&#x000e3;o de nomes gen&#x000e9;ricos em produtos farmac&#x000ea;uticos e d&#x000e1; outras
provid&#x000ea;ncias</source><publisher-name>Di&#x000e1;rio Oficial da Rep&#x000fa;blica Federativa do
Brasil</publisher-name><day>12</day><season>Fev.</season><year>1999</year></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence - NICE</collab></person-group><source>Chronic obstructive pulmonary disease -COPD guidelines. Management of
chronic obstructive pulmonary disease in adults in primary and secondary
care (partial update)</source><year>2010</year><date-in-citation content-type="access-date">cited 2012 May</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://publications.nice.org.uk/chronic-obstructive-pulmonary-disease">http://publications.nice.org.uk/chronic-obstructive-pulmonary-disease</ext-link></comment></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troosters</surname><given-names>T</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Gosselink</surname><given-names>R</given-names></name><name><surname>Decramer</surname><given-names>M</given-names></name></person-group><article-title>Pulmonary Rehabilitation in Chronic Obstructive Pulmonary
Disease</article-title><source>Am J Respir Crit Care Med</source><year>2005</year><volume>172</volume><fpage>19</fpage><lpage>38</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.200408-1109SO">http://dx.doi.org/10.1164/rccm.200408-1109SO</ext-link><pub-id pub-id-type="pmid">15778487</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourbeau</surname><given-names>J</given-names></name></person-group><article-title>Making pulmonary rehabilitation a success in COPD</article-title><source>Swiss Med Wkly</source><year>2010</year><volume>140</volume><fpage>w13067</fpage><lpage>w13067</lpage><pub-id pub-id-type="pmid">20809435</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacasse</surname><given-names>Y</given-names></name><name><surname>Goldstein</surname><given-names>R</given-names></name><name><surname>Lasserson</surname><given-names>TJ</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name></person-group><article-title>Pulmonary rehabilitation for chronic obstructive pulmonary
disease</article-title><source>Cochrane Database Syst Rev</source><year>2006</year><volume>4</volume><fpage>CD003793</fpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/14651858.CD003793.pub2">http://dx.doi.org/10.1002/14651858.CD003793.pub2</ext-link><pub-id pub-id-type="pmid">17054186</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miravitles</surname><given-names>M</given-names></name></person-group><article-title xml:lang="pt"> Avalia&#x000e7;&#x000e3;o econ&#x000f3;mica da doen&#x000e7;a pulmonar obstrutiva
cr&#x000f4;nica e de suas agudiza&#x000e7;&#x000f5;es. Aplica&#x000e7;&#x000e3;o na Am&#x000e9;rica Latina</article-title><source>J Bras Pneumol</source><year>2004</year><volume>30</volume><issue>3</issue><fpage>274</fpage><lpage>285</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1806-37132004000300015">http://dx.doi.org/10.1590/S1806-37132004000300015</ext-link></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rochester</surname><given-names>CL</given-names></name></person-group><article-title xml:lang="pt"> Exercise training in chronic obstructive pulmonary
disease</article-title><source>J Rehabil Res Dev</source><year>2003</year><volume>40</volume><issue>5</issue><fpage>59</fpage><lpage>80</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1682/JRRD.2003.10.0059">http://dx.doi.org/10.1682/JRRD.2003.10.0059</ext-link><pub-id pub-id-type="pmid">15074454</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourbeau</surname><given-names>J</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name><name><surname>Schwartzman</surname><given-names>K</given-names></name><name><surname>Ducruet</surname><given-names>T</given-names></name><name><surname>Nault</surname><given-names>D</given-names></name><name><surname>Bradley</surname><given-names>C</given-names></name></person-group><article-title>Economic benefits of self-management education in
COPD</article-title><source>Chest</source><year>2006</year><volume>130</volume><fpage>1704</fpage><lpage>1711</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.130.6.1704">http://dx.doi.org/10.1378/chest.130.6.1704</ext-link><pub-id pub-id-type="pmid">17166985</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halpern</surname><given-names>MT</given-names></name><name><surname>Stanford</surname><given-names>RH</given-names></name><name><surname>Borker</surname><given-names>R</given-names></name></person-group><article-title>The burden of COPD in the U</article-title><source>S.A: results from the Confronting COPD survey. Respir Med</source><year>2003</year><volume>97</volume><fpage>S81</fpage><lpage>S89</lpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0954-6111(03)80028-8">http://dx.doi.org/10.1016/S0954-6111(03)80028-8</ext-link><pub-id pub-id-type="pmid">12647946</pub-id></element-citation></ref></ref-list></back></article>